OP EU

Ono Pharmaceutical Europe (OP EU) is the European subsidiary of the Japanese pharmaceutical giant Ono Pharmaceutical Co., Ltd. The company focuses on the development and commercialization of innovative therapies, particularly in the fields of oncology, immunology, and neurology. OP EU is best known for its pioneering work in immuno-oncology, having co-developed the blockbuster PD-1 inhibitor Opdivo (nivolumab) in collaboration with Bristol Myers Squibb. The company maintains a robust clinical pipeline in Europe, targeting high-unmet-need areas such as primary central nervous system lymphoma and various solid tumors. Headquartered in London, OP EU serves as the strategic hub for the parent company's clinical development and regulatory activities across the European market.